Study evaluates use of extended-release niacin

03/28/2012 | PhysiciansBriefing.com

About 3.5% of patients with hyperlipidemia who used a combination of extended-release niacin and ezetimibe/simvastatin met the criteria for new onset diabetes at 64 weeks, compared with 2.6% in those taking E/S alone, according to a study in Diabetes Care. The researchers said those taking niacin had increased fasting glucose levels, but the cases went away without intervention.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY